Qing Sun, Xinlei Liao, Chenqian Wang, Guanglu Jiang, Jing Yang, Jianhong Zhao, Hairong Huang, Guirong Wang, Hao Li
Introduction. Nontuberculous mycobacteria (NTM) infections are increasing worldwide and are relatively resistant to many of the first- and second-line drugs to treat tuberculosis. Macrolide antibiotics, such as clarithromycin and azithromycin, are the key drugs for treating NTM infections. Fidaxomicin is a macrolide antibiotic that is widely used in treating Clostridium difficle (C.difficile) infections, and has high in vitro activity against Mycobacterium tuberculosis especially multidrug-resistant tuberculosis (MDR-TB) and has no cross-resistance with rifampicin...
June 2022: Journal of Medical Microbiology